Literature DB >> 11710727

Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy.

M Boers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11710727     DOI： 10.1002/1529-0131(200111)44:11<2703::aid-art451>3.0.co;2-e

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  5 in total

1.  Radiographic progression in rheumatoid arthritis: does it reflect outcome? Does it reflect treatment?

Authors:  D van der Heijde
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 2.  Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis.

Authors:  V Strand; R Landéwé; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

3.  Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description.

Authors:  M C Wick; S Lindblad; L Klareskog; R F Van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 4.  Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature.

Authors:  Takeshi Kuroda; Yoko Wada; Daisuke Kobayashi; Hiroe Sato; Syuichi Murakami; Masaaki Nakano; Ichiei Narita
Journal:  Rheumatol Int       Date:  2010-01-09       Impact factor: 2.631

5.  Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.

Authors:  Yoshiya Tanaka; Kazuhiko Yamamoto; Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Katsumi Eguchi; Akira Watanabe; Hideki Origasa; Toshiharu Shoji; Nobuyuki Miyasaka; Takao Koike
Journal:  Mod Rheumatol       Date:  2014-03-04       Impact factor: 3.023
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.